CD8A and neoplasm: Using next generation technologies (e.g., RNA-sequencing, ATAC-sequencing), it is possible to unbiasedly define tumor-specific signatures both in effector cells (CD4+ and CD8+ T cells), regulatory T cells, and myeloid cells.